

01997.043200



IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|---------------------------------|---|-------------------------|
| In re Application of: |) | |
| | : | Examiner: Not Yet Known |
| MARY COLLINS et al. |) | |
| | : | Group Art Unit: 1632 |
| Application No.: 10/806,611 |) | |
| | : | Confirmation No. 2470 |
| Filed: March 22, 2004 |) | |
| | : | Customer No. 45743 |
| For: TREATING IMMUNOLOGICAL |) | |
| DISORDERS USING AGONISTS OF | : | |
| INTERLEUKIN-21 / INTERLEUKIN-21 |) | |
| RECEPTOR | : | May 22, 2006 |

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, Applicants submit herewith a copy of an International Search Report, mailed April 10, 2006, in connection with Applicant's corresponding International Application PCT/US2004/008833, along with a copy of the Written Opinion in the same application.

Also submitted herewith is a copy of Form PTO-1449, which lists the five documents mentioned in the International Search Report mailed April 10, 2006 that are not already of record in the Information Disclosure Statement, filed June 22, 2004, in this


application. In addition, copies of the four non-U.S. patent references cited in that form are submitted herewith.

Applicants do not believe a fee is necessary in connection with the present Information Disclosure Statement. However, if a fee is necessary, such fee may be charged to Deposit Account 06-1205.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.


Respectfully submitted,



Joseph P. Pieroni
Attorney for Applicants
Registration No.: 53,469

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3800
Facsimile: (212) 218-2200

#484134

| | | | | | | | |
|---|-----------|--|---|---------------------|--------------------------------------|-------------|---------------------------------------|
| FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) | | | ATTY DOCKET NO. 01997.043200 | | APPLICATION NO. 10/806,611 | | |
|  | | | APPLICANT MARY COLLINS ET AL. | | | | |
| | | | FILING DATE March 22, 2004 | | GROUP 1632 | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | | 6,605,272 | 04/12/2005 | Novak et al. | 424 | 85.2 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES/NO/ OR ABSTRACT |
| | WO | 03/028630A2 | 04/10/2003 | PCT | A61K | | |
| | WO | 03/040313A2 | 05/15/2003 | PCT | C12N | | |
| | | | | | | | |
| | | | | | | | |
| OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| | | Aharoni et al., "Copolymer 1 Induces T Cells Of The T Helper Type 2 That Crossreact With Myelin Basic Protein And Suppress Experimental Autoimmune Encephalomyelitis," Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 10821-26 (Sept. 1997) | | | | | |
| | | Beebe et al., "The Role Of Interleukin-10 In Autoimmune Disease: Systemic Lupus Erythematosus (SLE) And Multiple Sclerosis (MS)," Cytokine Growth Factor Rev., Vol. 13, pp. 403-12, (2002) | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.